Increased BCR responsiveness in B cells from patients with chronic GVHD. - Wikidata - awgldk - TriplyDB

Increased BCR responsiveness in B cells from patients with chronic GVHD.

Increased BCR responsiveness in B cells from patients with chronic GVHD.

http://www.wikidata.org/entity/Q37670076

about

B cells in chronic graft-versus-host disease The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans Aberrant B-cell homeostasis in chronic GVHD Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.Circulating T follicular helper cells with increased function during chronic graft-versus-host disease A combined biomarker and clinical panel for chronic graft versus host disease diagnosis Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells.Cellular and molecular mechanisms in graft-versus-host disease.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel targets in the treatment of chronic graft-versus-host disease.Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.Mesenchymal Stem Cells May Ameliorate Nephrotic Syndrome Post-Allogeneic Hematopoietic Stem Cell Transplantation-Case Report Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.Changes in protein serum levels during stem cell transplantation.New and emerging therapies for acute and chronic graft versus host disease.B-cell targeting in chronic Graft-versus-Host disease.The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease.SYK Inhibition Induces Apoptosis in Germinal Center-Like B Cells by Modulating the Antiapoptotic Protein Myeloid Cell Leukemia-1, Affecting B-Cell Activation and Antibody Production.Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence.Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD

P2860

Q26861706-475C11E8-E212-47A0-A6B4-27C44312A44F Q28076264-7846D1BD-E6F8-42E2-B28F-013F41C3A4C3 Q33781179-3ED36A04-064E-4654-B2CF-BDCFD59420EF Q35171251-2E249D20-F7D6-42F9-8DB2-49A578D5EE76 Q35588726-F3D81731-E616-4964-847B-DBAE36989F3E Q35766798-10FC7949-1351-451F-B54B-AF152A190904 Q35784522-B8C5BFCF-D525-4AF3-AB9D-674FCE36E6FC Q36920466-EC5A7298-97F0-4C8D-B2C1-8DF25D68B33E Q37601730-C76B337E-3738-4EAF-B274-AD1F3BDD34AD Q37734489-9A3914C0-2395-4CEE-8947-0B27F83C32CE Q38392246-85F1EE55-C714-4A78-8074-6ADEF5E0665C Q38405199-EF1A6CD3-4425-4938-977C-543D84D0FE1C Q38656329-4E55FAE6-4940-4FF1-924B-5CFDC0DD1037 Q38661579-DD7B5924-7871-4C94-98E8-3D25ACAEC091 Q39002166-CECA6C9A-D268-4028-BCAC-E711CE566132 Q39023963-8FA879AF-5859-4C76-9641-D49F45271748 Q40122845-ABA443CA-D8C2-4CAF-BBEB-0276054D3413 Q41417888-23B5D855-D856-42C4-93E9-1DAD224E841E Q46428638-EE74ED53-2200-4CD6-93B4-A1DC5257B270 Q47709978-19F62E19-D17F-427B-AF56-F83BEA6D4238 Q47969259-9B399973-7680-4CE5-9522-FA6885A26239 Q49238507-8794CAB3-C877-43C2-9E0E-FFC82315D9F5 Q50044417-9FCD4111-6D5D-4926-822F-A77727DE812A Q52971841-FED49AFC-ABBB-458D-82E1-6B0111E60A0D Q54979506-F5858286-7C9D-4004-96E9-1895C9673BCB Q55045366-B4B52C54-183D-41D5-9526-F642E50FC269 Q58723868-F9E4FF08-E2BD-4467-BEA7-F89E35FE80F2 Q58782275-472EE2E2-465A-4789-96EE-F681CE6B9EAC

P2860

Increased BCR responsiveness in B cells from patients with chronic GVHD.

http://www.wikidata.org/entity/Q37670076

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Increased BCR responsiveness in B cells from patients with chronic GVHD.

@en

Increased BCR responsiveness in B cells from patients with chronic GVHD.

@nl

type

label

Increased BCR responsiveness in B cells from patients with chronic GVHD.

@en

Increased BCR responsiveness in B cells from patients with chronic GVHD.

@nl

prefLabel

Increased BCR responsiveness in B cells from patients with chronic GVHD.

@en

Increased BCR responsiveness in B cells from patients with chronic GVHD.

@nl

P1433

Q37670076-9957B627-93D3-4155-B678-9CED55969E7C

P1476

Q37670076-2F6476F2-9729-4455-AF48-C3B8EAE427B4

P2093

Q37670076-082368F7-5383-4615-8886-DB5799DD10B3

Q37670076-0C6FBA05-A304-42FB-8A8A-07528910A23A

Q37670076-10A7EDD6-6697-422B-9011-EE97EF9FE79E

Q37670076-216BA022-871A-48D4-A4AA-27D2736D1662

Q37670076-41BF9912-9491-4759-8B03-727A811B4EF2

Q37670076-4EA02B71-D61A-42FB-B437-D387CC08E230

Q37670076-67249C55-0560-49EF-B93A-3F15193F031D

Q37670076-683F2B75-BA20-46F1-BEE3-596F5CD1C34B

Q37670076-709E4230-9CAF-4A98-98A6-5225442319B4

Q37670076-A90382B0-066D-4E0A-9E46-9514C12A633A

P2860

Q37670076-07401120-774F-4833-A670-8F545128F060

Q37670076-1B6EF3AA-7006-48D6-94C6-23B294B40A97

Q37670076-22196794-E73B-491F-8277-F388365BCD06

Q37670076-39CA8C53-2BFC-4632-BED6-6E6D9D7CC3FA

Q37670076-477817A3-4E20-4548-8649-6B7D5DCC1174

Q37670076-4B645B18-647D-4C71-B740-ADB2D5BC7B2E

Q37670076-55D7A499-5F99-4615-85DA-C8F4ABD77BFA

Q37670076-57428805-2CF6-4678-8FEF-BB5A5F8661E8

Q37670076-577C418E-73D6-4FB7-B635-25CE69BE8561

Q37670076-5A946A98-2105-44D8-B845-492928529FF6

P304

Q37670076-EE0869AA-EE72-4CD3-AEE8-03114A8538D3

P31

Q37670076-F93B7E4E-F356-42A0-AEB1-F1B5FB142530

P356

Q37670076-B3646B10-7D4B-42A0-B7F2-7B323E22E391

P407

Q37670076-ACE14E93-94D4-4368-9753-62FB31F9C693

P433

Q37670076-55CBE4CE-9418-4554-A966-CE80179430AB

P478

Q37670076-6F34288C-576D-4501-B4F5-76609B2BE71E

P50

Q37670076-511C086E-7ED9-4112-9D05-0D8180048586

Q37670076-A4F75E18-929B-425A-AAD2-3689D2E7CEF2

P577

Q37670076-CBAB63F8-1ACF-4B6A-9D85-B7FD002C7550

P5875

Q37670076-9BC6A748-1323-4002-B0D4-67C3348808F8

P698

Q37670076-BBED4512-C1D2-46F3-8B73-15969C367218

P932

Q37670076-9FB82F0A-F40E-4AB1-8276-66AD8F888006

P356

BLOOD-2013-10-533562

P1433

P1476

Increased BCR responsiveness in B cells from patients with chronic GVHD.

@en

P2093

Allison M Deal

http://www.w3.org/2001/XMLSchema#string

Andrew Sharf

http://www.w3.org/2001/XMLSchema#string

David Rizzieri

http://www.w3.org/2001/XMLSchema#string

Jenna Wooten

http://www.w3.org/2001/XMLSchema#string

Jessica L Allen

http://www.w3.org/2001/XMLSchema#string

Kristy L Richards

http://www.w3.org/2001/XMLSchema#string

Madan Jagasia

http://www.w3.org/2001/XMLSchema#string

Matthew S Fore

http://www.w3.org/2001/XMLSchema#string

Mitchell E Horwitz

http://www.w3.org/2001/XMLSchema#string

Nelson J Chao

http://www.w3.org/2001/XMLSchema#string

P2860

BLNK: a central linker protein in B cell activation

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

Abnormal development and function of B lymphocytes in mice deficient for the signaling adaptor protein SLP-65

The adaptor protein BLNK is required for b cell antigen receptor-induced activation of nuclear factor-kappa B and cell cycle entry and survival of B lymphocytes

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

Advances in graft-versus-host disease biology and therapy.

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

CD20, AIF-1, and TGF-beta in graft-versus-host disease: a study of mRNA expression in histologically matched skin biopsies.

P304

2108-2115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-10-533562

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan S. Serody

Stefanie Sarantopoulos

P577

2014-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260213069

http://www.w3.org/2001/XMLSchema#string

P698

24532806

http://www.w3.org/2001/XMLSchema#string

P932

3968393

http://www.w3.org/2001/XMLSchema#string